Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT04566952 2020-10-30

ANLOLA

Phase 2 Unknown

68 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT04590625 2020-10-19

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Phase 2 Unknown

58 enrolled

Gynecologic

Ovarian Neoplasms

NCT03899610 2020-09-28

KGOG3046

Phase 2 Unknown

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT04383977 2020-05-12

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Phase 2 Unknown

54 enrolled

Gynecologic

Ovarian Neoplasms

NCT03556566 2019-08-30

V3-OVA

Phase 2 Unknown

20 enrolled

Gynecologic

Neoplasms, Ovarian Neoplasms

NCT03942068 2019-05-08

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Phase 2 Unknown

35 enrolled

Gynecologic

Ovarian Neoplasms

NCT03924882 2019-04-23

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Phase 2 Unknown

30 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

STROBE

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

NEO

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

BEACON

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

MITO28MaNGOov4

MITO 31

MITO 35a

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

GOGER-01

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Coala-T-CBD

ACTS

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

MITO 27

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

PORCH

MITO36

NIRVANA-R

A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Ovarian Dendritic Cell Vaccine Trial

Study of DP303c Injection in Patients With Advanced Ovarian Cancer

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

AVANIRA3

ANLOLA

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

KGOG3046

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

V3-OVA

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer